The influence of different classification standards of age groups on prognosis in high-grade hemispheric glioma patients

被引:17
作者
Chen, Jian-Wu [1 ]
Zhou, Chang-Fu [1 ]
Lin, Zhi-Xiong [1 ,2 ]
机构
[1] Fujian Med Univ, Dept Neurosurg, Affiliated Hosp 1, Fuzhou 350005, Fujian, Peoples R China
[2] Beijing Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China
关键词
High-grade glioma; Age; Prognosis; Univariate analysis; Multivariate analysis; FRACTIONATED STEREOTACTIC RADIOTHERAPY; ADJUVANT TEMOZOLOMIDE; GLIOBLASTOMA; CHEMOTHERAPY; MANAGEMENT; SURVIVAL; REIRRADIATION; BEVACIZUMAB; CONCOMITANT; RESECTION;
D O I
10.1016/j.jns.2015.06.036
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although age is thought to correlate with the prognosis of glioma patients, the most appropriate age-group classification standard to evaluate prognosis had not been fully studied. This study aimed to investigate the influence of age-group classification standards on the prognosis of patients with high-grade hemispheric glioma (HGG). This retrospective study of 125 HGG patients used three different classification standards of age-groups (<= 50 and >50 years old, <= 60 and >60 years old, <= 45 and 45-65 and >= 5 years old) to evaluate the impact of age on prognosis. The primary end-point was overall survival (OS). The Kaplan-Meier method was applied for univariate analysis and Cox proportional hazards model for multivariate analysis. Univariate analysis showed a significant correlation between OS and all three classification standards of age-groups as well as between OS and pathological grade, gender, location of glioma, and regular chemotherapy and radiotherapy treatment. Multivariate analysis showed that the only independent predictors of OS were classification standard of age-groups 550 and >50 years old, pathological grade and regular chemotherapy. In summary, the most appropriate classification standard of age-groups as an independent prognostic factor was <= 50 and >50 years old. Pathological grade and chemotherapy were also independent predictors of OS in post-operative HGG patients. (C) 2015 The Authors. Published by Elsevier B.V.
引用
收藏
页码:148 / 152
页数:5
相关论文
共 33 条
  • [1] [Anonymous], 2013, ONCOTARGETS THER, DOI DOI 10.2147/OTT.S33532
  • [2] BURGER PC, 1987, CANCER-AM CANCER SOC, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO
  • [3] 2-X
  • [4] Survival of high grade glioma patients depends on their age at diagnosis
    Casartelli, Gianluigi
    Dorcaratto, Alessandra
    Ravetti, Jean Louis
    Sola, Simona
    Vitali, Alessandro
    Merlo, Domenico Franco
    Frosina, Guido
    [J]. CANCER BIOLOGY & THERAPY, 2009, 8 (18) : 1719 - 1721
  • [5] Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy
    Chamberlain, M. C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (12) : 1225 - 1227
  • [6] Gliomatosis cerebri: clinical characteristics, management, and outcomes
    Chen, Selby
    Tanaka, Shota
    Giannini, Caterina
    Morris, Jonathan
    Yan, Elizabeth S.
    Buckner, Jan
    Lachance, Daniel H.
    Parney, Ian F.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2013, 112 (02) : 267 - 275
  • [7] Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas
    Cho, KH
    Hall, WA
    Gerbi, BJ
    Higgins, PD
    McGuire, WA
    Clark, HB
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (05): : 1133 - 1141
  • [8] Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial
    Collins, Vincent Peter
    Ichimura, Koichi
    Di, Ying
    Pearson, Danita
    Chan, Ray
    Thompson, Lindsay C.
    Gabe, Rhian
    Brada, Michael
    Stenning, Sally P.
    [J]. ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2014, 2
  • [9] Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas
    Combs, Stephanie E.
    Bischof, Marc
    Welzel, Thomas
    Hof, Holger
    Oertel, Susanne
    Debus, Juergen
    Schulz-Ertner, Daniela
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2008, 89 (02) : 205 - 210
  • [10] MGMT gene silencing and benefit from temozolomide in glioblastoma
    Hegi, ME
    Diserens, A
    Gorlia, T
    Hamou, M
    de Tribolet, N
    Weller, M
    Kros, JM
    Hainfellner, JA
    Mason, W
    Mariani, L
    Bromberg, JEC
    Hau, P
    Mirimanoff, RO
    Cairncross, JG
    Janzer, RC
    Stupp, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) : 997 - 1003